David C.K. Chu, Ph.D. Distinguished Research Professor Emeritus Pharmaceutical and Biomedical Sciences - Emeritus Office: Room 374, R.C Wilson Pharmacy Phone: (706) 542-5379 E-mail: dchu@rx.uga.edu

Biosketch

Professor	University of Georgia	Athens, GA
B.S. Pharmacy	Seoul National University	Korea	1964
M.S. Medicinal Chemistry	Idaho State University	Idaho	1970
Ph.D. Medicinal Chemistry	State University of New York	Buffalo, NY	1974

Honors and Awards
Elected Fellow of American Association of Advancement of Science 2002
Inventor of the Year Award (University of Georgia), 2002
NIH Merrit Award, (2001-2011)
University of Georgia Distinguished Research Professor, 1998-present
Editorial Advisory Board (Nucleosides, Nucleotides & Nucleic Acids), 1994-Present
Co-Founder & Chair, Scientific Advisory Board (Pharmasset), 1998-Present
NIH Advisory Committee Member (AIDS Emphasis panel-AARR3), 1998-2002
American Chemical Society (Northeast Georgia Section) Research Award, 1998
NIH Principal Investigator, 1986-Present

Research Interests
Nucleoside and carbohydrate chemistry
Antiviral chemotherapy (HIV, hepatitis B & C virus, West Nile virus, Smallpox virus and Epstein - Barr virus)
Cancer chemotherapy
Structure-based drug design & molecular modeling


Our drug discovery group at The University of Georgia College of Pharmacy has been involved in the discovery of antiviral and anticancer agents for the last 20 years. Our current focus is the structure-based drug design (HIV and hepatitis B & C virus) and chiral synthesis of carbohydrate-modified nucleosides as potential antiviral and anticancer agents. We are also investigating the HIV/HBV drug resistance and molecular mechanism of antiviral agents by molecular modeling approach. Our group has been fully funded by the National Institutes of Health as well as private foundations. Our group works closely with numerous well-known biology laboratories such as Emory University, Yale University, University of Alabama, Cornell University, Georgetown University, etc. Our drug discovery group is a nationally and internationally recognized academic center with many accomplishments in drug discovery as listed below:

• AZDU (CS-87) for AIDS (discovered 1987-Phase I/II-1999-discontinued)
  
• AZMC (CS-92) for AIDS (discovered 1988-Phase 1- discontinued)
  
• DAPD for AIDS (discovered 1992- currently Phase II clinical trials)
  
• L-OddC for cancer (discovered 1993-currently Phase II/III clinical trials)
  
• L-FMAU for hepatitis B virus (discovered 1993-currently Phase II clinical trials)
  
• L-IOddU for Epstein-Barr virus (discovered 1996-currently preclinical)
  

Representative Publications
Wang, J.N.; Jin, Y.H.; Rapp, K.L.; Schinazi, R.F.; Chu, C. K. D- and L-2’3’-Dihydro-2’, 3’-dideoxy-3’-fluoro-carbocyclic nucleosides: Anti-HIV activity and mechanism of resistance. J. Med. Chem. 2007, in press.

Choo, H., Chen, X.; Yadav, V.; Schinazi, R.F.; Chu, C.K. Synthesis and Anti-HIV activity of D-and L-thietanose nucleosides, J. Med. Chem. 2006, 49, 1635-1647.

Cho, J.H.; Sidwell, R.W.; Prichard, M.N.; Kern. E.R.; Chu C.K. Synthesis of cyclopentenol carbocyclic nucleosides as potential antiviral agents against Orthopoxviruses and SARS, J. Med. Chem. 2006, 49, 1140-1148.

Arumugham, B.; Kim, H.J.; Prichard, M.N.; Kern, E.R.; Chu, C.K. Synthesis and antiviral activity of 7-deaza neplanocin A against orthopoxviruses (vaccinia and cowpox virus). Bioorg. Med. Chem. Letts. 2005, Bioorg. Med. Chem. Lett. 2006, 16, 285-287.

Liang, Y.Z.; Narayanasamy, J.; Schinazi, R.F.; Chu, C.K. Phosporamidate and phosphate prodrugs of (-)--D- (2R, 4R)-dioxolane-thymine (DOT): synthesis, anti-HIV activity and stability study, Bioorg. Med. Chem., 2006, 14, 2178-2189.

Chu, C.K.; Gadthula, S.; Chen, X.; Choo, H.A.; Olgen, S.Y.; Barnard, D.L.; Sidwell, R.W. Antiviral activity of nucleoside analogs against SARS-coronavirus (SARS-CoV), Antiviral Chem. Chemother, 2006, 17, 285-289.